ProPhase Labs, Inc. (NASDAQ:PRPH – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 154,100 shares, a drop of 25.2% from the October 15th total of 206,100 shares. Based on an average daily trading volume, of 83,200 shares, the days-to-cover ratio is currently 1.9 days.
ProPhase Labs Price Performance
PRPH opened at $0.75 on Friday. The business has a 50 day moving average of $2.20 and a 200-day moving average of $3.29. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.58 and a quick ratio of 1.44. ProPhase Labs has a 1-year low of $0.66 and a 1-year high of $7.48.
ProPhase Labs (NASDAQ:PRPH – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.25). The company had revenue of $2.47 million during the quarter. ProPhase Labs had a negative net margin of 217.64% and a negative return on equity of 60.20%. On average, equities analysts expect that ProPhase Labs will post -1.23 EPS for the current fiscal year.
Institutional Inflows and Outflows
ProPhase Labs Company Profile
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Recommended Stories
- Five stocks we like better than ProPhase Labs
- What Investors Need to Know to Beat the Market
- Top-Performing Non-Leveraged ETFs This Year
- What is the Hang Seng index?
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- How to Invest in Small Cap Stocks
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.